Could These Findings Dramatically Change the Opportunities for COVID-19 Vaccine Stocks?
New twists and turns continue to come in the scramble to develop a COVID-19 vaccine.
Last week, Moderna (NASDAQ: MRNA) reported more great results from a phase 1 study of its vaccine candidate mRNA-1273. This week, medical journal The Lancet published positive results for AZD1222, the COVID-19 vaccine candidate being developed by AstraZeneca (NYSE: AZN) and the University of Oxford. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) also announced more good news for experimental coronavirus vaccine BNT162b1.
There have also been two recent findings that potentially impact all of the drugmakers developing vaccines against SARS-CoV-2. Could these findings dramatically change the prospects for COVID-19 vaccine stocks?
Source Fool.com
